Royalty Pharma (RPRX) Total Debt: 2019-2025
Historic Total Debt for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $8.9 billion.
- Royalty Pharma's Total Debt rose 17.59% to $8.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 billion, marking a year-over-year increase of 17.59%. This contributed to the annual value of $7.6 billion for FY2024, which is 24.08% up from last year.
- Royalty Pharma's Total Debt amounted to $8.9 billion in Q3 2025, which was up 11.79% from $8.0 billion recorded in Q2 2025.
- In the past 5 years, Royalty Pharma's Total Debt ranged from a high of $8.9 billion in Q3 2025 and a low of $5.9 billion during Q1 2021.
- In the last 3 years, Royalty Pharma's Total Debt had a median value of $7.6 billion in 2024 and averaged $7.3 billion.
- Examining YoY changes over the last 5 years, Royalty Pharma's Total Debt showed a top increase of 24.08% in 2024 and a maximum decrease of 13.79% in 2024.
- Quarterly analysis of 5 years shows Royalty Pharma's Total Debt stood at $7.2 billion in 2021, then dropped by 1.22% to $7.1 billion in 2022, then decreased by 13.79% to $6.1 billion in 2023, then rose by 24.08% to $7.6 billion in 2024, then increased by 17.59% to $8.9 billion in 2025.
- Its last three reported values are $8.9 billion in Q3 2025, $8.0 billion for Q2 2025, and $7.6 billion during Q1 2025.